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95% CI 6.5–9.3; group 2: 12.9, CI 11.3–14.4) but not direct
treatment costs (€2.033 vs. €1.991 respectively). There was a
trend for higher indirect costs in patients in severity group 2
(€5.120, CI €2.717–€7.523 vs. €6.796, CI €3997–€9596). CON-
CLUSION: Total annual costs of new cases covered by DGUV
with conﬁrmed occupational etiology is estimated to amount to
€55million, considering also patientswith suspected occupational
etiology increases costs to €96 million. Total costs of prevalent
cases can be expected to amount tomultiples of this ﬁgure. Disease
severity, although impacting patient’s QoL, has little inﬂuence on
treatment patterns and costs. Indirect costs, by far the most
important cost factor, tend to increase with severity.
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OBJECTIVE: The aim of this study was to determine the annual
direct costs of treating bacterial conjunctivitis (BC) in the United
States. METHODS: A systematic review of the medical literature
was supplementedwith information fromdetailed physician inter-
views on resource utilization associated with bacterial conjunc-
tivitis therapy in theUnited States. Data on the annual incidence of
BC was obtained from an analysis of the National Ambulatory
Medical Care Survey (NAMCS) database for the year 2005.
Cost estimates for resource utilization such as physician visits and
prescription drugs were taken from standard cost reference
sources. Due to the acute nature of BC no cost discounting was
performed. The economic perspective presented is that of the
payer. All costs are expressed in 2007 USD. RESULTS: The
number of BC cases in the United States for 2005 was estimated at
4,016,544, yielding an estimated annual incidence rate of 135.46
per 10,000. Base-case analysis estimated the direct cost of treating
patients with bacterial conjunctivitis in the United States at
US$765,063,696. One-way sensitivity analysis assuming either a
20% variation in the annual incidence of bacterial conjunctivitis
or treatment costs generated a cost range of US$612,050,957 to
US$918,076,435. Two-way sensitivity analysis assuming a 20%
variation in both the annual incidence of bacterial conjunctivitis
and treatment costs occurring simultaneously resulted in an
estimate cost range of US$489,627,912 to US$1,101,711,002.
CONCLUSION: This study reports the ﬁrst known estimate of
the direct costs of treating and managing patients with bacterial
conjunctivitis in the United States. The economic burden of this
condition is substantial. Our estimates represent conservative
amounts because indirect costs were not considered in the analy-
sis. This information may prove useful to decision makers with
respect to the adequate allocation of health care resources neces-
sary to address the economic burden of BC in the United States.
PSS23
PROACTIVE USE OFTACROLIMUS 0.03% OINTMENT IN
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OBJECTIVE: To describe treatment outcomes and to evaluate
resource utilization and associated cost of proactive use of
tacrolimus ointment (PU) versus standard use of tacrolimus oint-
ment (SU) in children with moderate or severe atopic dermatitis
(AD) over a period of 12 months. METHODS: A pan-European,
phase III multicentre randomized clinical trial FG-506-06-41
‘CONTROL’ was conducted. After randomization patients (2–15
years old) applied tacrolimus 0.03% ointment (PU) or vehicle
ointment (SU) at the usually affected areas twice per week for
12 months. Disease exacerbations were treated using open-label
tacrolimus 0.03% ointment twice daily. Resource utilization data
(e.g. for ointments, drugs, doctor consultations, out-of-pocket-
expenses, absence from school) were collected alongside the
clinical trial by caregiver questionnaires, prospectively. Costs
of pooled resource data were determined using German unit cost
data. Direct and indirect costs were considered from third party
payer (TPP), caregiver, and societal perspectives. RESULTS: 146
patients were included in the analysis, 75 PU patients (53%
moderately affected) and 71 SU patients (51% moderately
affected). Mean age of patients was 7 years (SD 3.9/4.5) in both
treatment groups. Mean + SD body surface area in both groups
was 1.0 + 0.4 m2. The mean number of disease exacerbations
requiring substantial therapeutic intervention in the PU and SU
arms was 1.7 + 2.2 and 3.4 + 3.2 (p < 0.001), respectively. In
patients with severe AD the mean total annual cost per patient
was higher in the standard regimen €2,002 + 2,315 compared to
PU €1,571 + 1,122. In the subgroup of severely affected 2–6
year-old patients these cost differences were larger in favour of
tacrolimus ointment: €1,465 + 837 (PU) versus €2,253 + 2,855
(SU). In moderately affected patients there were no cost differ-
ences: €1,233 + 1,507 (PU) and €1,136 + 1,494 (SU). CONCLU-
SION: Proactive treatment with tacrolimus 0.03% ointment is
more effective and leads to cost savings in comparison to stan-
dard treatment with tacrolimus 0.03% ointment, especially in
children with severe AD.
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OBJECTIVE: Acne is a common dermatological condition and
impacts millions of adolescent and adult lives in the United States
(US). The purpose of this study was to accurately quantify the
cost per episode for the treatment of acne in the US and to
examine disparities in treatment costs. METHODS: Information
was collected from the PharMetrics Integrated Patient-centric
Database, a large collection of administrative claims in the year
2004. The database included more than 80 public and private
health care plans included in the database, representing approxi-
mately 9.6 million unique patients. Analysis was performed using
the Total Resource Utilization (TRU) Benchmarks process, a
descriptive methodology which organizes and separates informa-
tion from the third-party database, into accessible benchmarks
for comparison. RESULTS: There are many different drug treat-
ment therapies that can be used to treat acne which can range in
price dramatically. The average acne episode cost $777.19, with
pharmacy costs representing 59.5% and outpatient costs repre-
senting 39.1%. Inpatient services were reported in only 0.1% of
acne episodes and were associated with $9,297.56 in costs. For
patients diagnosed with acne, pharmacy visits represented 85.5%
of all episodes. Average outpatient costs were $303.99, attribut-
able to 3.73 outpatient services with 2.18 of these services were
physician visits. The lowest average total episode costs were
found in the South-central region and were $624.05. The highest
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average total episode costs were found in the Northeast region
and were $856.50. Average outpatient costs in the Northeast
region were the highest in the country at $377.64—the range for
other regions was $240.70-$285.93. CONCLUSION: Much
diversity exists in the cost of treating acne across different seg-
ments of the United States. Future research should be done to
determine what the underlying factors are when accounting for
the discrepancies in cost per episode of acne.
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OBJECTIVE: To determine the most cost-effective Wet AMD
treatment alternative in Mexico. METHODS: A decision tree
with Bayesian approach and a Markov chain considering the
probabilities of increasing, decreasing or maintaining visual
acuity (VA) through eight health states based on VA from 20/20
to 20/400 due to the use of a pharmacological alternative, with a
time horizon of 5 years and institutional perspective, were per-
formed. The discounting rate was three percent for costs and
beneﬁts. Adverse events and their treatment costs, for every
alternative were considered; costs, beneﬁts and probabilities of
transition data were estimated from the meta-analysis with avail-
able published literature, including the MARINA and ANCHOR
studies, validated by a panel of Mexican experts through the
Delphi technique. Study comparators examined were Ranibi-
zumab (RAN), photodynamic therapy with Verteporﬁn (PDTV),
pegaptanib sodium (PEG) and standard care (STD). Sensitivity
analysis was one-way and probabilistic (acceptability curve,
analysis of components for the ellipse method). RESULTS:
Patients using Ranibizumab get more beneﬁts (RAN = 2.71
QALY; PDTV = 2.03 QALY; PEG = 1.89 QALY; STD = 1.78
QALY), with the lowest total cost per treatment (RAN =
$43,984 USD; STD = $63,531 USD; PDTV = $83,546 USD;
PEG = $92,247 USD) and the lowest cost per QALY (RAN =
$16,257 USD/QALY; STD = $35,749 USD/QALY; PDTV =
$41,074 USD/QALY; PEG = $48,263 USD/QALY). Incremental
analysis showed Ranibizumab to be the dominant alternative.
Net beneﬁts are greater with Ranibizumab independent of will-
ingness to pay. Acceptability curves showed absolute superiority
for Ranibizumab. The conﬁdence interval of 95% with the ellipse
method showed Ranibizumab to be dominant in 95% of the
cases with a willingness to pay of $924USD. The sensitivity
analysis on efﬁciency and costs of Ranibizumab in an interval of
50%, was robust with the base analysis. CONCLUSION:
Ranibizumab is the most cost-effective Wet AMD treatment
alternative; it offers the greatest beneﬁts with the lowest cost.
Sensitivity analyses showed the robustness of the base study.
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OBJECTIVE: Measure incremental cost-utility and budget
impact of etanercept vs. inﬂiximab in moderate-to-severe PSO
with >10% body surface area involvement. METHODS: We
used a Markov decision analysis to compare 2 strategies for PSO:
etanercept label dose (50 mg BIW x12 wks, then 25 mg BIW);
and inﬂiximab label dose (5 mg/kg IV at wks 0, 2, and 6, then
5mg/kg Q8W). We derived 60 probability estimates through
systematic review of the literature and labels, varying each of
these estimates in each sensitivity analysis. We adopted an MCO
payer’s perspective, and included cost estimates for a compre-
hensive list of related resources as determined by Medicare and
the Red Book. Qulaity-adjusted life-years (QALYs) were esti-
mated by applying utilities from the literature to reported efﬁcacy
as measured by PASI scores. We calculated the incremental cost
per QALY gained and incremental per-member per month
(PMPM) budget impact in a hypothetical MCO of 1 million lives
(assuming a 1% prevalence of moderate-to-severe PSO). We dis-
counted costs and effects at 3% per year over a 2-year time
horizon. RESULTS: In the base-case analysis, etanercept yielded
1.68 QALYs at a total cost of $28,442 over the 2-year horizon,
and inﬂiximab yielded 1.78 QALYs at a cost of $49,906. Com-
pared to etanercept, inﬂiximab cost an incremental $214,640/
QALY-gained. In sensitivity analysis, inﬂiximab dominated
etanercept when the cost of inﬂiximab fell by 55% (from $691 to
$312 per 100 mg vial), or when the cost of etanercept increased
83% (from $187 to $342 per 25 mg vial). In budget impact
modeling, inﬂiximab cost an incremental $8.94 PMPM vs. etan-
ercept. CONCLUSION: Decision analysis was used to model
relative cost-utility and budget impact of biologic therapies in
PSO—a chronic health condition. The incremental cost and
budget impact of inﬂiximab vs etanercept exceeds standard
benchmarks in the absence of comparative effectiveness from
head to head trials.
SENSORY SYSTEMS DISORDERS—
Patient-Reported Outcomes
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OBJECTIVE: To evaluate persistence among glaucoma patients
with prostaglandin therapy during the ﬁrst therapy year.
METHODS: Patients with latanoprost (LAT), bimatoprost
(BIM), or travoprost (TRAV) dispensed during January 1, 2004–
December 31, 2004 were screened for inclusion (Ingenix
managed care database). Index agent = ﬁrst agent ﬁlled; index
date = ﬁll date; follow-up = 358 days. Patients excluded if:
age < 40 years; not continuously enrolled for 180 days before/
358 days after index date; had ocular hypotensive dispensed or
had no glaucoma diagnosis within 180 days before index date.
First year persistence measures: whether last ﬁll had sufﬁcient
days supply to achieve medication possession at year’s end;
number of days for which index agent was available (days
covered). Possible inconsistencies between quantity dispensed
and reported days supply addressed by multiplying claimed days
supply with alternative measures from the literature. Models of
associations between index agent and medication possession
(logistic regression) and days covered (linear regression) were
adjusted for gender, age, and previous ocular hypertension diag-
nosis. RESULTS: A total of 7783 patients met inclusion criteria
(LAT, n = 4994; BIM, n = 1464; TRAV, n = 1415). Overall medi-
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